Preview Newsletter
Morcellation Media Monitoring 01/04/2016
-
Ethicon Morcellator Settlements Reached in Some Cases, As Discovery Schedule Outlined in MDL
Dec 30, 2015 | AboutLawsuits.com
By Austin Kirk
Court documents suggest that settlements have been reached in several Ethicon morcellation lawsuits brought on behalf of women who had aggressive uterine cancers spread during a laparoscopic hysterectomy or fibroid removal surgery, but discovery is set to move forward in dozens of other cases that have not been resolved. -
Cancer Deaths Following Morcellation Lead Congressman to Call for Investigation
Dec 28, 2015 | AboutLawsuits.com
By Irvin Jackson
Following the deaths of several women from involving use of power morcellators, a Pennsylvania congressman is asking federal health regulators to investigate whether some hospitals violated regulations by failing to report the problems. -
Ethicon Claims Ignorance of Early Morcellator Problems
Dec 31, 2015 | Top Class Actions
By Paul Tassin
Amid litigation over whether power morcellators can aggravate existing cancer, Johnson & Johnson subsidiary and morcellator manufacturer Ethicon has denied being aware of any reportable adverse events related to those devices until relatively recently. -
Wrongful Death Power Morcellation Lawsuit Filed in Missouri
Dec 28, 2015 | Top Class Actions
By Laura Schultz
The family members of a deceased Missouri woman have filed a wrongful death power morcellation lawsuit against Ethicon, a subsidiary of Johnson & Johnson which manufactures medical devices. -
Ethicon Power Morcellator Lawsuits Alleging Device Spreads Uterine Cancer Progress After Status Conference
Dec 29, 2015 | Press Release
By Banville Law
Banville Law reports on the release of new information regarding Ethicon power morcellator lawsuits involved in MDL number 2652. The initial status and schedule conference for these cases was held on November 18th of 2015. It was held following the U.S. Judicial Panel for Multidistrict Litigation moved to consolidate the cases involved. This consolidation was possible due to the fact that all cases involved presented similar allegations against Ethicon-brand morcellators (a subdivision of Johnson & Johnson). The cases in the MDL will be heard in the U.S. District Court for the District of Kansas, and will be overseen by the Honorable Judge Kathryn H. Vratil. -
Lawsuits Against Ethicon Allege Power Morcellator Device Accelerates Uterine Cancer
Dec 30, 2015 | Press Release
By Banville Law
Banville Law reports on a recent surge in lawsuits filed against multiple laparoscopic power morcellator manufacturers, all of which synonymously allege that the devices can spread and advance cancer while shredding uterine fibroid tissue during hysterectomies, myomectomies, or other gynecological surgeries involving fibroids. -
Power Morcellator Lawsuit Alleges Tool Caused Fatal Uterine Cancer Diagnosis For Woman
Dec 31, 2015 | Press Release
By Banville Law
Banville Law reports on another lawsuit filed against power morcellator manufacturer Ethicon, (a subdivision of Johnson & Johnson). The suit was filed on behalf of a deceased woman by her family. Their complaint alleges that the woman’s death was ultimately caused by the use of a laparoscopic power morcellator during her hysterectomy, which exposed, spread, and advanced previously hidden cancer cells.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Morcellation
Full Text of Stories Below
-
Ethicon Morcellator Settlements Reached in Some Cases, As Discovery Schedule Outlined in MDL
Dec 30, 2015 | AboutLawsuits.com
By Austin Kirk
Court documents suggest that settlements have been reached in several Ethicon morcellation lawsuits brought on behalf of women who had aggressive uterine cancers spread during a laparoscopic hysterectomy or fibroid removal surgery, but discovery is set to move forward in dozens of other cases that have not been resolved.
Power morcellators are surgical devices used during minimally invasive hysterectomy and myomectomy procedures, allowing surgeons to cut up and remove the uterus or uterine fibroids through a small incision in the abdomen. However, a number of manufacturers of these hysterectomy surgical devices now face lawsuits alleging they are unreasonably dangerous and caused hidden cancers contained within the uterus to be spread throughout the abdomen.
Since October, all product liability lawsuits filed against Johnson & Johnson’s Ethicon subsidiary have been consolidated in the federal court system as part of an MDL, or multidistrict litigation. Before concerns about the link between morcellators and cancer emerged early last year, Ethicon was the leading manufacturer of the surgical device in the U.S.
Cases filed by women and families throughout the U.S. are centralized for pretrial proceedings before U.S. District Judge Kathyryn H. Vratil in the District of Kansas to reduce duplicative discovery into common issues in the cases, avoid conflicting rulings from different judges and to serve the convenience of the parties, witnesses and the courts.
In a scheduling order (PDF) issued on December 24, Judge Vratil outlined a discovery plan for the litigation, which calls for written discovery to begin early next month and indicates that most non-expert discovery will be completed within one year. This may allow the court to schedule a series of bellwether trials to begin by mid-2017, if agreements are not reached by the manufacturer to resolve large numbers of cases.
It appears that Ethicon has already reached some morcellator settlements with women and families, as at least two attorneys previously appointed to serve in leadership roles in the litigation are seeking to resign from the Plaintiffs’ Steering Committee (PSC), indicating that all of their clients have settled their claims in the MDL.
Despite indications that Ethicon is willing to consider settling morcellation cancer lawsuits early in the litigation process, Judge Vratil indicated in the order that it remains premature for the court to require mediation or any other form of alternative dispute resolution (ADR) at this point. However, Judge Vratil indicates that the Court itends to revisit the issue of ordering Ethicon morcellator settlement negotiations at later status conferences.
Power Morcellator Cancer Concerns
Each of the lawsuits against Ethicon involve similar allegations that the medical device manufacturer knew or should have known about the risk that laparoscopic morcellation may disseminate uterine cancer, yet failed to adequately warn the medical community or women deciding to undergo a minimally invasive procedure instead of a traditional hysterectomy or myomectomy.
The litigation has emerged since April 2014, when the FDA estimated that one out of every 350 women undergoing surgery for symptomatic uterine fibroids may actually have undiagnosed and unsuspected sarcoma contained within the uterus. For these women, morcellators may rapidly spread cancerous cells throughout the body, rapidly upstaging leiomyosarcoma, endometrial stromal sarcoma or other uterine cancers to an advanced stage that is difficult to treat and often fatal.
Two FDA advisory panels were convened by the agency, which determined that there was no safe way to use power morcellators for uterine fibroid removal. However, the panels could not agree on whether to recommend that the agency demand a power morcellator recall or simply add a black box warning.
Shortly afterwards, Ethicon, who previously dominated the power morcellator market, decided that it will no longer manufacturer the devices, essentially issuing an Ethicon power morcellator recall after acknowledging that there is no way to make the devices safer.
While the FDA has allowed laparoscopic morcellators to remain on the market, with much stronger warnings about the potential cancer risks, many hospitals and doctors have announced that they will no longer perform hysterectomy or myomectomy procedures with morcellation, indicating that there is no way to justify the risk.
In addition to cases over Ethicon morcellators, similar lawsuits have been filed against other manufacturers of the hysterectomy surgical devices, including Karl Storz, Richard Wolf Medical Instruments, and Gyrus ACMI.
As part of the coordinated proceedings in the Ethicon morcellators MDL, if the manufacturer fails to settle or otherwise resolve cases, it is expected that Judge Vratil will schedule a series of “bellwether” trials to help the parties gauge how juries may respond to certain evidence and testimony that is likely to be repeated throughout the litigation.
The next status conference before Judge Vratil is scheduled for January 6, 2016, at which time the Court is expected to discuss proposed orders regarding discovery in cases where plaintiffs are extremely ill or at risk of dying, as well as orders regarding product identification and preservation of pathology evidence in the cases.
-
Cancer Deaths Following Morcellation Lead Congressman to Call for Investigation
Dec 28, 2015 | AboutLawsuits.com
By Irvin Jackson
Following the deaths of several women from involving use of power morcellators, a Pennsylvania congressman is asking federal health regulators to investigate whether some hospitals violated regulations by failing to report the problems.
In a a letter sent to George Karavetsos, head of the FDA Office of Criminal Investigations on December 18, Representative Mike Fitzpatrick requested that the agency investigate Brigham and Women’s Hospital, Rochester General Hospital, and University of Rochester Medical Center. The letter indicates that the hospitals did not report when women died of advanced stage cancer that was likely spread by the use of power morcellators during laparoscopic hysterectomies and myomectomies for uterine fibroid removal.
The Pennsylvania Republican is asking the FDA to investigate whether the hospitals violated their legal reporting obligations by not reporting the deaths, as serious questions continue to remain unanswered about how federal regulators failed to identify the potential cancer risks from morcellation for years after the devices were introduced.
Power morcellators became increasingly popular over the past decade, providing doctors a way of cutting up and removing the uterus or uterine fibroids through a minimally invasive, laparoscopic procedure. While these procedures reduce recovery time and the risk of infections or other complications, morcellators have been largely abandoned within the medical community since it was discovered last year that they pose an unreasonable risk for women with hidden cancers, which doctors are unable to detect before the procedure.
“For over 2 decades since the power morcellator was first cleared for use on patients, the FDA’s Medical Device Reporting regulations failed to catch the severe dangers posed to women’s health by morcellation,” the letter states. “In fact, the first time the FDA received a report of death or serious injury was neither from a user facility nor a device manufacturer. It was ‘from a physician citing the case of a family member who has a disseminated cancer that was suspected to have resulted from a procedure in which a power morcellator was used.; It should not have taken a family devastated by this device to raise the issue to the FDA. Had the regulations works [sic] as intended, it is likely many women’s lives could have been spared from the horrific consequences of morcellation.”
FDA estimates suggest that about one out of every 350 women undergoing surgery for symptomatic uterine fibroids may actually have undiagnosed or unsuspected sarcoma contained within the uterus, leading the agency to first warn about the morcellation cancer risks in April 2014.
While the agency has allowed laparoscopic morcellators to remain on the market, with much stronger warnings about the potential risks, many hospitals have announced that they will no longer perform hysterectomy or myomectomy procedures with morcellation, indicating that there is no way to justify the risk.
Power morcellator cancer concerns first came to public awareness in late 2013, when Dr. Hooman Noorchashm launched a campaign to halt their use after his wife, Dr. Amy Reed, was diagnosed with leiomyosarcoma following a morcellation procedure. The couple has since moved from Boston to Fitzpatrick’s district in Pennsylvania, where he has taken up their cause.
In August, Fitzpatrick was one of about a dozen lawmakers who sent a letter to the Government Accountability Office (GAO) calling for an investigation into the FDA’s approval and oversight process for power morcellators. That investigation is currently underway.
As more families learn about the link between the devices and uterine cancers diagnosed in recent years, a growing number of morcellation cancer lawsuits are being filed against manufacturers of the devices, alleging that they failed to adequately warn women or the medical community about the risks associated with the minimally invasive procedures.
If consumers and the medical community had been provided accurate and complete information about the potential risk that morcellators may disseminate aggressive cancers throughout the body, plaintiffs allege that they would have elected to undergo alternative procedures for removal of uterine fibroids.
Amid a mounting number of cases filed throughout the federal court system against Johnson & Johnson’s Ethicon subsidiary, which was previously the leading manufacturer of the medical devices, the U.S. Judicial Panel on Multidistrict Litigation established consolidated federal proceedings the litigation in October.
All product liability lawusits filed over the spread of leiomyosarcoma, endometrial stromal sarcoma or other uterine cancers following use of an Ethicon morcellator are centralized before U.S. District Judge Kathryn H. Vratil in the District of Kansas, as part of a federal MDL, or multidistrict litigation.
-
Ethicon Claims Ignorance of Early Morcellator Problems
Dec 31, 2015 | Top Class Actions
By Paul Tassin
Amid litigation over whether power morcellators can aggravate existing cancer, Johnson & Johnson subsidiary and morcellator manufacturer Ethicon has denied being aware of any reportable adverse events related to those devices until relatively recently.
In a statement to the website The Cancer Letter, a representative of Ethicon said the company first became aware of power morcellator adverse events in December 2013. Since then, Ethicon has reported all such events to the FDA that have come to the company’s attention, the representative said.
At issue is the potential of power morcellators to spread previously-undetected cancer. Power morcellators are surgical devices used to remove large masses of tissue during laparoscopic surgery. They work by cutting larger masses into pieces small enough to be removed through the small incisions used in laparoscopic surgery.
Using laparoscopic techniques for procedures like hysterectomy or uterine fibroid surgery offers the patient certain benefits, like reduced risk of infection and shorter recovery time.
According to a safety communication issued by the FDA in April 2014 and updated in November 2014, however, the use of power morcellators during some types of gynecological surgery may inadvertently cut up previously undetected cancerous tissue and spread it elsewhere in the body, causing a rapid and dangerous upstaging of that cancer.
The FDA estimates that as many as one in 350 women undergoing hysterectomy or uterine fibroid surgery may have a uterine sarcoma that went undetected prior to surgery. The agency says that there is currently no reliable way to detect a uterine sarcoma prior to surgery.
What Did Ethicon Know?
Ethicon’s statement to The Cancer Letter comes after a November 2015 U.S. House of Representatives committee hearing on the matter. In that hearing, Rep. Tim Murphy of Pennsylvania noted that Ethicon received a letter from Pennsylvania pathologist Dr. Robert Lamparter as early as 2006 expressing concerns about the possibility that power morcellators could spread cancer.
Ethicon told The Cancer Letter that Dr. Lamparter was only seeking advice on how to collect and evaluate specimens following power morcellation surgery. The company says that because the doctor did not report his experience as an actual event with a particular patient, his letter did not trigger Ethicon’s duty to report an adverse event.
Dr. Lamparter says the incident he wrote to Ethicon about was a “near miss.” The patient went in for a hysterectomy that was originally planned to be done laparoscopically.
When the surgery couldn’t be completed that way due to adhesions, it was completed abdominally. Dr. Lamparter says that when the uterus was removed intact, the surgeon found a cancer that would have been spread if the uterus had been morcellated.
After a series of email exchanges between Dr. Lamparter and Ethicon representatives, Ethicon closed its investigation of the issue. Today, Dr. Lamparter says his 2006 correspondence with Ethicon shows they were aware of the possibility of morcellator cancer years before the first such adverse event was reported to the FDA.
Johnson & Johnson has since recalled all Ethicon power morcellators from the market.
Morcellator Cancer Lawsuits
Meanwhile, several plaintiffs across the U.S. have come forward with morcellator cancer lawsuits. Generally, plaintiffs claim that power morcellators are unreasonably dangerous devices and that the manufacturers failed to adequately warn patients and physicians about the danger of morcellator cancer.
In October 2015, the federal Judicial Panel on Multidistrict Litigation transferred 28 of these claims to a federal court in Kansas for consolidated pretrial proceedings. Future morcellator cancer lawsuits will also be transferred into this multidistrict litigation.
-
Wrongful Death Power Morcellation Lawsuit Filed in Missouri
Dec 28, 2015 | Top Class Actions
By Laura Schultz
The family members of a deceased Missouri woman have filed a wrongful death power morcellation lawsuit against Ethicon, a subsidiary of Johnson & Johnson which manufactures medical devices.
The wrongful death lawsuit alleges that a power morcellator caused the spread of previously undetected cancer after the medical device was used in a surgery to remove the deceased woman’s uterine fibroids.
According to the morcellation cancer lawsuit, the deceased woman had uterine fibroids surgically removed. A uterine fibroid is a noncancerous growth that develops in a woman’s uterus. These growths often develop during a woman’s childbearing years.
Power Morcellation Risks
Power morcellators allow surgeons to remove these growths or tumors in a minimally invasive way. The use of power morcellators was marketed as a way to reduce recovery time and risk of infection.
A morcellator is a small device with whipping blades that shred tissue so that it can easily be removed from the body. Power morcellators were commonly used to remove fibroids, a woman’s uterus, fallopian tubes, and ovaries.
The US Food and Drug Administration (FDA) issued a safety warning regarding the risk associated with using power morcellators and spreading undetected cancer cells. According to the warning an estimated one-out-of-every-350 women who undergo gynecological surgeries have undetected cancer cells within their uterine fibroids.
When a morcellator is used the cancer cells may be released and spread throughout the patient’s body. This can rapidly increase the spread of cancer causing it to be discovered in a much later stage of advancement.
The Food and Drug Administration suggests women avoid using power morcellators during gynecological surgeries in order to avoid these risks.
Morcellation Lawsuits
The lawsuit mentioned above is just one of many power morcellation lawsuits that have been filed against various medical device manufacturers.
Due to the number of lawsuits filed regarding power morcellation devices, Ethicon, the above named defendant, has stopped manufacturing the device and in 2014, issued a recall for their morcellator devices that were on the market.
As a result of the large quantity of power morcellation lawsuits filed the litigation against the medical device manufacturers has been consolidated to form multidistrict litigation. This funnels the cases before a single judge for pretrial motions and discovery proceedings.
In some situations, a few cases will be tried early as bellwether trials. This helps foster settlement negotiations between the various plaintiffs and defendants by giving them an idea of the monetary value associated with their cases.
Product liability attorneys are currently looking to assist persons who may have a potential power morcellation lawsuit.
Deciding to bring a power morcellator lawsuit is a big decision that should be made after weighing the facts and circumstances of each individual’s situation. Successful plaintiffs may be awarded significant monetary compensation for their pain, suffering, and medical bills.
Power morcellator lawsuits like these also help hold large pharmaceutical and medical device companies accountable for the actions and to their consumers.
-
Dec 29, 2015 | Press Release
By Banville Law
Banville Law reports on the release of new information regarding Ethicon power morcellator lawsuits involved in MDL number 2652. The initial status and schedule conference for these cases was held on November 18th of 2015. It was held following the U.S. Judicial Panel for Multidistrict Litigation moved to consolidate the cases involved. This consolidation was possible due to the fact that all cases involved presented similar allegations against Ethicon-brand morcellators (a subdivision of Johnson & Johnson). The cases in the MDL will be heard in the U.S. District Court for the District of Kansas, and will be overseen by the Honorable Judge Kathryn H. Vratil.
In this first conference, pretrial proceedings are said to have been discussed. The consolidation of these cases helps to fast-track the litigation process, which should also help these pretrial proceedings run more smoothly. Case consolidation helps to avoid duplicate discovery, different rulings from multiple judges, and also conserves the time and money of those involved.
Plaintiffs involved in MDL lawsuits commonly allege that Ethicon failed to warn consumers of the cancer risks associated with using laparoscopic power morcellation to remove uterine fibroids. The United States Food and Drug Administration has also stepped forward with a safety warning discussing the surgical procedure, stating that most women should avoid undergoing power morcellation during hysterectomies and myomectomies involving fibroids due to the fact that the tool could uncover and spread previously undetected cancer cells. They also estimated that 1 in every 350 women who do undergo these gynecological procedures may have uterine sarcomas they are unaware of. Plaintiffs allege that by exposing and disseminating these cancer cells, power morcellators can accelerate the cancer, causing high grade, life-threatening cancer diagnosis post surgery.
Plaintiffs have indicated that Ethicon has been made aware of these risks, yet has hidden this information from the public. Until the FDA’s safety warning was released, Ethicon continued to market the devices. After the statement, however, they ceased production of the tools and recalled those currently in use. Unfortunately, many other manufacturers still produce power morcellators, and they continue to be used during laparoscopic gynecological surgeries today.
Several recent studies support the plaintiff allegations, connecting laparoscopic power morcellation on uterine fibroids to the spread of cancer. While cases currently involved in the MDL are prepared for trial, it is expected that others will continue to be filed.
The attorneys at Banville Law are working to ensure that anyone who underwent laparoscopic power morcellation and who was subsequently diagnosed with cancer will have the opportunity to explore their legal rights. These individuals may be entitled to compensation. Banville Law is currently offering complimentary morcellator consultations to those involved.
To ask questions or request more information, please contact Banville Law by calling (888) 997-3792.
-
Lawsuits Against Ethicon Allege Power Morcellator Device Accelerates Uterine Cancer
Dec 30, 2015 | Press Release
By Banville Law
Banville Law reports on a recent surge in lawsuits filed against multiple laparoscopic power morcellator manufacturers, all of which synonymously allege that the devices can spread and advance cancer while shredding uterine fibroid tissue during hysterectomies, myomectomies, or other gynecological surgeries involving fibroids.
Manufacturers named in the lawsuits include Ethicon (a subdivision of Johnson & Johnson), Lumenis Ltd., Olympus, Blue Endo, Cook Urological Inc., Karl Storz GmbH, Smith & Nephew, Richard Wolf GmbH, and LiNA Medical. All lawsuits filed against Ethicon were consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL number 2652 in Kansas.
The Ethicon cases were able to be consolidated due to the fact that they were filed against the same defendant and all shared similar allegations. The consolidation will help to “fast-track” the legal process, avoiding duplicate discovery and different decisions from multiple judges. It also helps to conserve time and finances of everyone involved.
In 2014, the U.S. Food and Drug Administration issued a safety warning regarding laparoscopic power morcellation, indicating that most women should never undergo this procedure due to the risk of exposing and spreading cancer cells from uterine fibroids which may have been previously undetected. The FDA also estimated that nearly 1 in every 350 women undergoing these gynecological surgeries on their uterine fibroids may have hidden cancer cells which, if spread with morcellation, could advance, significantly impairing the life-expectancy of the patient.
A power morcellator enters the abdomen through a tiny incision where it quickly spins blades designed to shred troublesome fibroid tissue. The procedure provides a minimally invasive option to open gynecological surgery. After the fibroid tissue is shred into small pieces, it can be pulled up through a tube connected to the morcellator, removing it from the body. While it does this, plaintiffs allege, it also disseminates cancer cells, creating advanced and high-grade cancer that is difficult to treat and often fatal.
The attorneys at Banville Law understand the incredible seriousness of this issue. Many of the lawsuits filed have been done on behalf of loved ones who have since passed away from cancer. Banville Law is working to ensure that anyone who has undergone laparoscopic power morcellation to remove uterine fibroids and who was subsequently diagnosed with cancer will be able to explore their legal rights. These women may be entitled to legal action and significant compensation. The attorneys at Banville Law are currently offering free legal consultations to everyone affected.
To ask questions or request additional information on laparoscopic power morcellation, please contact the attorneys at Banville Law by calling (888) 997-3792.
-
Power Morcellator Lawsuit Alleges Tool Caused Fatal Uterine Cancer Diagnosis For Woman
Dec 31, 2015 | Press Release
By Banville Law
Banville Law reports on another lawsuit filed against power morcellator manufacturer Ethicon, (a subdivision of Johnson & Johnson). The suit was filed on behalf of a deceased woman by her family. Their complaint alleges that the woman’s death was ultimately caused by the use of a laparoscopic power morcellator during her hysterectomy, which exposed, spread, and advanced previously hidden cancer cells.
Details of this lawsuit explain that the woman underwent her hysterectomy in order to remove uterine fibroids that had become painful. During this procedure, in order to perform a less-invasive surgery, surgeons used an Ethicon-brand power morcellator tool. The device was inserted into the woman’s lower abdomen where it works by rapidly spinning small blades which shred the fibroid tissue. These shredded pieces of tissue are later able to be removed from the body through the incision.
As this woman’s family alleges, and as many other plaintiffs claim, as the morcellator does this, it can expose previously undetected cancer cells and its motion can disseminate these cells throughout the body. This accelerates the cancer, advancing its grade and significantly impairing its treatability. Often, these cancers continue to grow despite treatment and become fatal.
In this particular case, the woman passed away from aggressive and widespread cancer less than two years after undergoing power morcellation. She was ultimately diagnosed with metastatic uterine cancer which, despite many attempts at various treatments, only continued to spread and grow. The family alleges that had the woman’s cancer not been spread by the power morcellator tool, it may have been contained and able to be treated more successfully. Cancer cells that are encapsulated within a uterine fibroid are virtually impossible to detect prior to surgery.
The U.S. Food and Drug Administration has issued a safety warning which discussed power morcellation during gynecological surgery. They informed women that they should refrain from undergoing this procedure on uterine fibroids because of the risk of spreading hidden cancer cells. Additionally, they estimated that around 1 out of every 350 women who undergo power morcellation for hysterectomies and myomectomies may have uterine cancer cells they are unaware of.
As power morcellation lawsuits continue to mount, all suits against Ethicon brand morcellators have been consolidated to form multidistrict litigation number 2652 by the U.S. Judicial Panel on Multidistrict Litigation. They are being overseen by the Honorable Judge Kathryn H. Vratil in the U.S. District of Kansas. Ethicon morcellators have since been recalled, and the company is no longer producing them, however, many other manufacturers continue to make and market the tool.
The attorneys at Banville Law are dedicated to ensuring that everyone who has undergone power morcellation and was subsequently diagnosed with cancer will have the opportunity to explore all of their legal rights. These individuals and their families may be entitled to legal action and significant compensation. Banville Law is currently offering these individuals free legal consultations.
To request additional information on power morcellator lawsuits, or to ask questions, please contact Banville Law by calling (888) 997-3792.
Client Attorney Privileged/Attorney Work Product/At Request of Counsel
Morcellation
Full Text of Stories Below
Add recipients
Suggested